NHS: Drugs

(asked on 10th January 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to Annex B of NHS England’s publication, Biological Medicines Commissioning Framework, published on 12 September 2017, how commissioners should assess value added services offered by manufacturers including (a) patient support programmes and (b) other value added services.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 19th January 2018

Through competitive tenders undertaken by NHS England’s commercial medicines unit, value added services are not scored as part of the award criteria and the competition focuses only on the specific product. Companies are free to include any information concerning additional services they may offer with the tender.

Reticulating Splines